Lexeo to Acquire Mantle Therapeutics for Up to $21.3M, Adding Four Frataxin-Targeting FA Programs
核心洞察
Lexeo Therapeutics signed a definitive agreement to acquire private clinical-stage Mantle Therapeutics (搜索) for $8.3 million upfront plus up to $13.0 million in clinical and regulatory milestones.
The deal adds four frataxin (搜索)-targeting programs spanning oral small molecules, a brain-shuttle fusion protein and an ASO Fab conjugate for Friedreich ataxia (搜索).
Mantle's clinical-stage oral candidate LX3010 (搜索) showed an approximately six-point mFARS improvement at 16 weeks and a mean nine-fold frataxin (搜索) increase in muscle biopsies.
Lexeo Therapeutics has entered a definitive agreement to acquire privately held, clinical-stage Mantle Therapeutics (搜索), adding four frataxin (搜索)-targeting programs to its Friedreich ataxia (搜索) pipeline and extending its reach into the central nervous system manifestations of the disease beyond its lead cardiac gene therapy. The transaction carries $8.3 million in upfront consideration, payable in a combination of cash and equity, plus up to $13.0 million in success-based clinical and regulatory milestone payments, for total potential consideration of $21.3 million. Subject to customary closing conditions, the deal is expected to close in the third quarter of 2026.
The acquisition was signed on September 16, 2026, and announced alongside three new research collaborations supporting cerebellar-targeted development of frataxin (搜索) gene therapy. Lexeo said the transactions are being pursued within its existing balance sheet capacity, with cash runway guidance unchanged into 2028. Future investment decisions will be guided by predefined scientific, clinical, strategic and financial criteria, and the company expects to provide a program prioritization update in early 2027 and to submit an investigational new drug application for its next Friedreich ataxia (搜索) development candidate in 2027.
"Our objective is to build the best-in-class therapeutic platform for the treatment of Friedreich ataxia (搜索)," said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. "LX2006 remains our highest priority as the best-in-class treatment for FA cardiomyopathy, and the addition of Mantle's pipeline, combined with new research collaborations will broaden our technology platform with multiple complementary CNS-targeted therapeutic strategies designed to restore frataxin (搜索) in the brain."
Four Acquired Programs Spanning Multiple Modalities
The acquired portfolio covers oral small molecules, a recombinant protein and an RNA-targeted conjugate.
LX3010 (搜索) (MTL-104) is a clinical-stage oral combination therapy designed to increase frataxin (搜索) expression while addressing mitochondrial function and oxidative stress through complementary mechanisms, HDAC (搜索) inhibition and Nrf2 (搜索) activation. Early clinical data across 11 Friedreich ataxia (搜索) patients include an approximately six-point improvement in modified Friedreich Ataxia Rating Scale (mFARS) scores at 16 weeks and a mean nine-fold increase in frataxin protein levels from baseline in muscle biopsies.
LX3030 (搜索) (MTL-707) is a preclinical oral, tissue-penetrant small molecule under 500 Da designed to increase production of endogenous frataxin (搜索) in the central nervous system. It is a third-generation benzamide HDAC (搜索) inhibitor that builds on published clinical work showing oral benzamide HDAC inhibitors increase frataxin in FA patients through epigenetic modulation and acetylation of chromatin. Preclinical studies have demonstrated robust increases in frataxin.
LX3050 (搜索) (MTL-501) is a preclinical recombinant human frataxin (搜索) fused to a proprietary anti-TfR1 Fab, intended to directly replace the deficient frataxin protein. The construct uses a TfR1-targeting brain shuttle designed to cross the blood-brain barrier and increase delivery of frataxin to the brain. In vitro studies have shown dose-responsive improvements in measures of mitochondrial function.
LX3070 (搜索) (MTL-801) is a discovery-stage antisense oligonucleotide Fab conjugate designed to stabilize FXN (搜索) mRNA and thereby increase translation of endogenous frataxin (搜索) protein. The program combines an RNA-targeted mechanism conjugated to a proprietary anti-TfR1 Fab, with in vitro studies demonstrating dose-responsive increases in frataxin.
Together with LX2006, Lexeo said the expanded portfolio gives it the technology to evaluate multiple biologic theses for treating Friedreich ataxia (搜索) in the brain. The complementary therapies will be evaluated both as standalone treatments and in combination with LX2006, and all future clinical trials are expected to include a treatment arm for patients previously treated with LX2006.
Three Collaborations Target Sequential CNS Dosing
Lexeo established three collaborations to evaluate cerebellar-targeted sequential dosing of frataxin (搜索) gene therapy, all designed to be complementary to systemically administered LX2006.
Under a sponsored research agreement, Weill Cornell Medicine will evaluate intra-cisternal administration of LX2006 following systemic dosing in large animal models. The collaboration is intended to advance understanding and translation of cerebellar-targeted sequential dosing and to evaluate dosing parameters and immune-suppression strategies that may support repeat administration.
Lexeo also entered an option agreement with Vivet Therapeutics (搜索) for the opportunity to secure an exclusive license to VTX-PID (搜索), an IgG-degrading enzyme intended to support immune-suppression strategies that may expand the treatable population with immunization against AAV and facilitate repeat administration of LX2006.
A third option agreement with Apertura Gene Therapy (搜索) provides the opportunity to license a novel, intravenously administered, blood-brain barrier-crossing capsid (CapX) expected to enable a less invasive route of administration to the CNS following initial systemic administration of LX2006.
Lexeo said it intends to evaluate the outcomes of these collaborations against predefined scientific, clinical and financial criteria and to prioritize investment in opportunities with the greatest potential to advance into clinical development.
LX2006 Remains the Lead Program
LX2006 continues to advance enrollment in the SUNRISE-FA 2 pivotal study, which Lexeo describes as its highest operational and capital-allocation priority. The program remains on track to deliver topline data in the second half of 2027. Lexeo believes LX2006 has the potential to become the first disease-modifying therapy specifically targeting Friedreich ataxia cardiomyopathy (搜索).
Friedreich ataxia (搜索) is a rare inherited disease affecting the nervous system and heart, causing progressive difficulties with balance, coordination, mobility and other daily activities. It is caused by reduced levels of frataxin (搜索), a protein essential for normal cellular function. Many patients currently face limited treatment options, particularly for neurological symptoms.
Lexeo is a New York City-based clinical-stage company developing therapeutics for cardiovascular and neurological genetic diseases. Its portfolio includes LX2006 for Friedreich ataxia (搜索) and LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy. The company is also introducing an expanded vision reflecting its focus on genetic diseases with high unmet need in both the cardiovascular and neurological space, aligning with its growing Friedreich ataxia platform and portfolio across modalities outside gene therapy.